Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 4Urinary Bladder Neoplasms 3Uterine Cervical Neoplasms 2Breast Neoplasms 2Uterine Neoplasms 1Urogenital Neoplasms 1Rectal Neoplasms 1Pancreatic Neoplasms 1Neoplasm Metastasis 1Esophageal Neoplasms 1Endometrial Neoplasms 1Breast Neoplasms, Male 1Brain Neoplasms 1

Interventions

pembrolizumab 157Gemcitabine 139Capecitabine 121Paclitaxel 119Fluorouracil 116Oxaliplatin 110Bevacizumab 104Nivolumab 97Leucovorin 97Docetaxel 93Cisplatin 91Irinotecan 88Carboplatin 86Radiosurgery 83Cyclophosphamide 71Cetuximab 70Magnetic Resonance Spectroscopy 68Trastuzumab 56Specimen Handling 56Biopsy 56Radiotherapy 55Ipilimumab 52Everolimus 48Pemetrexed 47Drug Therapy 45Albumin-Bound Paclitaxel 44130-nm albumin-bound paclitaxel 43Doxorubicin 41Fulvestrant 38aldesleukin 37

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Neoplasm Metastasis × ferumoxtran-10 × Clear all
NCT04261777 2026-04-28

Ferumoxtran-10-enhanced MRI in Prostate Cancer Patients

Saving Patients' Lives Medical B.V.

Phase 3 Terminated
172 enrolled
Genitourinary

Neoplasm Metastasis, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡